breast cancer
Conditions
Interventions
Treatment group:Capecitabine
Observation group:None
Sponsors
Suining Central Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Female aged from 18 to 70 years old; 2. ECOG score: 0 to 2; 3. Diagnosed as invasive breast cancer by pathological method; 4. Clinical or pathological stage of II or III; 5. Accepted surgical procedure with or without a neoadjuvant chemotherapy; 6. The status is disease-free after the standard adjuvant treatment; 7. Breast cancer subtypes are HER-2 positive or triple negative breast cancer, and not accept the anti-target therapy; 8. Recurrence risk is midrange or high; 9. Patient has the desire to participate in this study, and signed inform consent form.
Exclusion criteria
Exclusion criteria: 1) Patients are in period of pregnancy and breast-feeding, or have a desire of pregnancy; 2) With any severe underlying diseases, can't sustain the chemotherapy; 3) With any malignant tumor simultaneous or heterochronic; 4) Already in any other clinical trial; 5) With a psychiatric disorder or can't comply with the treatment; 6) Having the contraindication to capecitabine; 7) Unable to cooperate the data collection with researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival;Safety index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Local recurrence-free survival;Distance disease-free survival;Breast cancer specific survival; | — |
Countries
China
Contacts
Public ContactHongwei Yang
Suining Central Hospital
Outcome results
None listed